Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 85.8% in October

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 15,600 shares, a decline of 85.8% from the October 15th total of 110,200 shares. Based on an average daily volume of 67,600 shares, the short-interest ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are sold short.

Qualigen Therapeutics Trading Up 4.8 %

NASDAQ:QLGN traded up $0.19 during trading hours on Wednesday, reaching $4.12. 127,300 shares of the company’s stock were exchanged, compared to its average volume of 94,273. Qualigen Therapeutics has a 12 month low of $3.71 and a 12 month high of $39.13. The business’s 50-day simple moving average is $7.42 and its two-hundred day simple moving average is $10.35.

Qualigen Therapeutics (NASDAQ:QLGN) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($10.00) earnings per share for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.